AR109644A2 - Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal - Google Patents

Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal

Info

Publication number
AR109644A2
AR109644A2 ARP170102528A ARP170102528A AR109644A2 AR 109644 A2 AR109644 A2 AR 109644A2 AR P170102528 A ARP170102528 A AR P170102528A AR P170102528 A ARP170102528 A AR P170102528A AR 109644 A2 AR109644 A2 AR 109644A2
Authority
AR
Argentina
Prior art keywords
oral cavity
systemic treatment
pharmaceutical composition
pradofloxacine
bacterial diseases
Prior art date
Application number
ARP170102528A
Other languages
English (en)
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34201505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR109644(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of AR109644A2 publication Critical patent/AR109644A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Pradofloxacina, caracterizada porque se usa para el tratamiento de sistémico de una enfermedad bacteriana en la cavidad bucal. Reivindicación 2: Una composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal caracterizada porque comprende un antibiótico de 8-ciano-quinolona, donde el antibiótico de 8-ciano-quinolona es la pradofloxacina.
ARP170102528A 2003-08-13 2017-09-13 Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal AR109644A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10337191A DE10337191A1 (de) 2003-08-13 2003-08-13 Neue Verwendung von Chinolon-Antibiotika

Publications (1)

Publication Number Publication Date
AR109644A2 true AR109644A2 (es) 2019-01-09

Family

ID=34201505

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP040102624A AR045093A1 (es) 2003-08-13 2004-07-23 Composición farmacéutica y uso de antibióticos de quinolona
ARP170102528A AR109644A2 (es) 2003-08-13 2017-09-13 Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP040102624A AR045093A1 (es) 2003-08-13 2004-07-23 Composición farmacéutica y uso de antibióticos de quinolona

Country Status (32)

Country Link
US (1) US8658645B2 (es)
EP (1) EP1656143B1 (es)
JP (2) JP5122814B2 (es)
KR (1) KR101209119B1 (es)
CN (1) CN100571702C (es)
AR (2) AR045093A1 (es)
AT (1) ATE528004T1 (es)
AU (2) AU2004266452A1 (es)
BR (1) BRPI0413509A (es)
CA (1) CA2535637C (es)
CY (1) CY1112167T1 (es)
DE (1) DE10337191A1 (es)
DK (1) DK1656143T3 (es)
ES (1) ES2374728T3 (es)
GT (1) GT200400156A (es)
HR (1) HRP20120019T1 (es)
IL (1) IL173655A (es)
LU (1) LU91883I2 (es)
MX (1) MXPA06001597A (es)
MY (1) MY162652A (es)
NO (1) NO333116B1 (es)
NZ (1) NZ545261A (es)
PE (1) PE20050341A1 (es)
PL (1) PL1656143T3 (es)
PT (1) PT1656143E (es)
RU (1) RU2367437C2 (es)
SI (1) SI1656143T1 (es)
TW (1) TWI367095B (es)
UA (1) UA85685C2 (es)
UY (1) UY28465A1 (es)
WO (1) WO2005018641A2 (es)
ZA (1) ZA200601167B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
FR2896416B1 (fr) * 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
DE102006049520A1 (de) 2006-10-20 2008-04-24 Bayer Healthcare Ag Verfahren zur Herstellung von Pradofloxacin
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
WO2010069493A1 (de) * 2008-12-18 2010-06-24 Bayer Animal Health Gmbh Verbesserte wirkstoffkombination enthaltend ein antibiotikum und einen nichtsteroidalen entzündungshemmer (nsaid)
CN102988280B (zh) * 2012-10-08 2014-03-19 新乡医学院 一种加雷沙星滴眼剂
JP6358868B2 (ja) * 2014-06-17 2018-07-18 Ｄｓファーマアニマルヘルス株式会社 オルビフロキサシンを含有する製剤組成物
CN106831795B (zh) * 2017-01-16 2018-12-21 石家庄学院 喹诺酮异土木香内酯衍生物及其制备和应用
CA3098060A1 (en) 2018-04-25 2019-10-31 Bayer Animal Health Gmbh Process for the hydrolysis of quinolone carboxylic esters
AU2020393384A1 (en) * 2019-11-28 2022-06-09 Bayer Aktiengesellschaft Substituted aminoquinolones as DGKalpha inhibitors for immune activation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62205060A (ja) * 1986-03-04 1987-09-09 Kyorin Pharmaceut Co Ltd ８位置換キノロンカルボン酸誘導体
DE3702393A1 (de) * 1987-01-28 1988-08-11 Bayer Ag 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo- 3-chinolincarbonsaeuren, verfahren zu ihrer herstellung und diese enthaltende antibakterielle mittel
US6323213B1 (en) * 1996-02-23 2001-11-27 Bayer Aktiengesellschaft Possibly substituted 8-cyano-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolin carboxylic acids and their derivatives
TW415943B (en) * 1996-06-28 2000-12-21 Bayer Ag 7-(3-vinyl-1,4-piperazin-1-yl)-substituted quinolonecarboxylic acids
DE19633480A1 (de) * 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
DE19652219A1 (de) * 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(1-Aminomethyl-2-oxa-7-azabicyclo[3.3.0]oct-7-yl)-chinolon- und naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
WO1999010351A1 (fr) * 1997-08-22 1999-03-04 Dainippon Pharmaceutical Co., Ltd. Derives d'acide pyridonecarboxylique et intermediaires aux fins de leur preparation
DE19962470A1 (de) * 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika

Also Published As

Publication number Publication date
LU91883I2 (fr) 2013-04-12
PE20050341A1 (es) 2005-07-07
ES2374728T3 (es) 2012-02-21
NO333116B1 (no) 2013-03-04
RU2006107497A (ru) 2006-08-10
RU2367437C2 (ru) 2009-09-20
NO20061127L (no) 2006-03-08
PT1656143E (pt) 2012-01-12
JP2012211170A (ja) 2012-11-01
TW200517110A (en) 2005-06-01
HRP20120019T1 (hr) 2012-02-29
SI1656143T1 (sl) 2012-03-30
HK1098687A1 (zh) 2007-07-27
IL173655A (en) 2013-07-31
DK1656143T3 (da) 2012-02-06
KR20060061353A (ko) 2006-06-07
JP5122814B2 (ja) 2013-01-16
CY1112167T1 (el) 2015-12-09
AR045093A1 (es) 2005-10-12
JP2007501819A (ja) 2007-02-01
AU2004266452A1 (en) 2005-03-03
BRPI0413509A (pt) 2006-10-10
WO2005018641A2 (de) 2005-03-03
WO2005018641A3 (de) 2005-10-06
UA85685C2 (ru) 2009-02-25
CA2535637A1 (en) 2005-03-03
AU2011200356B2 (en) 2012-01-12
IL173655A0 (en) 2006-07-05
MXPA06001597A (es) 2006-05-19
US20070082911A1 (en) 2007-04-12
ATE528004T1 (de) 2011-10-15
CN100571702C (zh) 2009-12-23
CA2535637C (en) 2011-11-08
TWI367095B (en) 2012-07-01
UY28465A1 (es) 2005-03-31
GT200400156A (es) 2005-03-23
EP1656143A2 (de) 2006-05-17
EP1656143B1 (de) 2011-10-12
NZ545261A (en) 2009-11-27
ZA200601167B (en) 2007-04-25
KR101209119B1 (ko) 2012-12-07
AU2011200356A1 (en) 2011-02-17
PL1656143T3 (pl) 2012-03-30
CN1867335A (zh) 2006-11-22
DE10337191A1 (de) 2005-03-17
MY162652A (en) 2017-06-30
US8658645B2 (en) 2014-02-25

Similar Documents

Publication Publication Date Title
AR109644A2 (es) Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal
UY27175A1 (es) Nueva sal succinato de o-desmetil- venlafaxina
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
IL174154A (en) History of GLP-1 New Pharmaceutical Preparations Containing Them and Using It to Make Medicines
GB0118238D0 (en) Medicaments
GB0112836D0 (en) Medicaments
CY1108992T1 (el) Η χρηση του υαλουρονικου οξεος για την παρασκευη συνθεσεων για τη θεραπευτικη αντιμετωπιση υποτροπιαζουσων αφθων της στοματικης κοιλοτητας
AR032293A1 (es) Estuche farmaceutico
WO2004032866A3 (en) Therapeutic formulations
BR0112847A (pt) Uso de uma forma de dosagem sólida
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
HRP20080438T3 (en) Octenidine-containing lozenges used against inflammatory oral and pharyngeal diseases
EP1781277A4 (en) COMBINED COMPOSITION
ATE401074T1 (de) Synergistische antibakterielle formulierung und herstellungsmethode
AU2002358082A1 (en) Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
UY27679A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faríngea.
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
SE0001916D0 (sv) Novel formulation
AR043370A1 (es) Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga
BR0210632A (pt) Tratamento de doença parasìtica
SE0202365D0 (sv) New formulation and use thereof
DE50202227D1 (de) Arzneimittel enthaltend einen effektor des glutathionmetabolismus zusammen mit alpha-liponsäure im rahmen der nierenersatztherapie
RS50523B (sr) Farmaceutska kompozicija koja sadrži cink-hijaluronat kompleks za lečenje multiple skleroze
MY141008A (en) Oral formulations of deoxypeganine and their uses
BRPI0518584A2 (pt) combinaÇço, composiÇço farmacÊutica, mÉtodo de tratar cÂncer, e, kit

Legal Events

Date Code Title Description
FC Refusal